Inpatient Update

Mason Turner, MD
  • 5.0 (1)
  • MEDICINE

Inpatient Update delivers short, practical reviews of new studies that matter to hospitalists—focused on what actually changes decisions on rounds tomorrow. Efficient, evidence-based, and built for the working clinician. 

Episodes

  1. MAR 11

    Episode 4: Faster Hypernatremia Correction & Long-Acting Antibiotics for Staph Bacteremia (w/ Dr. Kevin Baker)

    Send a text Episode 4: Faster Hypernatremia Correction & Long-Acting Antibiotics for Staph Bacteremia With Special Guest Dr. Kevin Baker In this episode of Inpatient Update, Dr. Mason Turner is joined by hospitalist Dr. Kevin Baker to discuss two studies that challenge long-held dogma in inpatient medicine: Faster correction of hypernatremia — is the traditional “go slow” rule actually harming patients?Dalbavancin for Staph aureus bacteremia (DOTS Trial) — can two long-acting antibiotic injections replace weeks of IV therapy and PICC lines?Practical take-homes, real-world discussion, and what to change on rounds tomorrow (with a couple of bourbons). Articles & PubMed Links Clinical outcomes of early fast compared to slow sodium correction rate in adults with severe hypernatremia: A comparative effectiveness study Journal of Critical Care (2025) Key Findings Faster correction associated with lower 30-day mortalityShorter ICU length of stayShorter hospital length of stayNo signal for neurologic complications from rapid correctionSupporting data from prior studies: 2023 JAMA observational cohort Faster correction associated with lower mortality No neurologic complications reported2025 Journal of Critical Care meta-analysis Faster correction not associated with worse outcomesTakeaway For adult hypernatremia, especially in critically ill patients, more aggressive correction appears safe and may improve outcomes. Pubmed: https://pubmed.ncbi.nlm.nih.gov/41240509/ Dalbavancin for Treatment of Staphylococcus aureus Bacteremia: The DOTS Randomized Clinical Trial JAMA 2025 Compared: Standard Therapy 4–8 weeks IV antibioticsCefazolin / anti-staphylococcal penicillin (MSSA)Vancomycin or daptomycin (MRSA)vs Dalbavancin Strategy 1500 mg IV day 11500 mg IV day 8Long-acting lipoglycopeptide with ~14-day half-life, allowing completion of therapy without PICC lines. Population Complicated Staph aureus bacteremiaKey Results Clinical efficacy: Dalbavancin: 73%Standard therapy: 72%Microbiologic success: Dalbavancin: 98.8%Standard therapy: 96.3%Met criteria for non-inferiority. Takeaway For selected patients with cleared Staph aureus bacteremia, two doses of dalbavancin may replace weeks of IV antibiotics and PICC lines. Potential advantages: Avoids central line complicationsSimplifies discharge planningUseful in patients with difficult social situations or IV access concernsPubmed: https://pubmed.ncbi.nlm.nih.gov/40802264/ Practice-Changing Takeaways Hypernatremia: Faster correction appears safe in adults and IMPROVES mortality.Staph bacteremia: Long-acting dalbavancin offers a PICC-free alternative for completing therapy in selected patients.Hospital medicine continues to move toward shorter and simpler antibiotic strategies.

    34 min

  2. FEB 25

    Episode 3: Stop the Aspirin in CAD? Shorter Antibiotics for Bacteremia? (with Dr. Andres Ospina)

    Send a text In this episode of Inpatient Update, Dr. Mason Turner is joined by Dr. Andres Ospina, fellow hospitalist, to discuss two recent trials with immediate impact on hospital practice: Aspirin plus anticoagulation in chronic coronary disease (AQUATIC Trial) — does keeping aspirin help or harm when long-term anticoagulation is started?Seven vs fourteen days of antibiotics for bloodstream infection (BALANCE Trial) — can we safely cut bacteremia treatment in half?Practical take-homes, clear links to the evidence, and what to change on rounds tomorrow. Articles & PubMed Links Aspirin in Patients with Chronic Coronary Syndrome Receiving Oral Anticoagulation (AQUATIC Trial) New England Journal of Medicine (October 2025) Key Findings: Higher morbidity and mortality with dual therapy (HR 1.53)Bottom Line: In stable CAD >6 months from revascularization, if anticoagulation is started, stop the aspirin. Pubmed: https://pubmed.ncbi.nlm.nih.gov/40888725/ Antibiotic Treatment for Bloodstream Infection (BALANCE Trial) New England Journal of Medicine (November 2024) Multicenter, randomized, non-inferiority trial (n≈3,600) Bottom Line: In uncomplicated bacteremia with source control and no severe immunocompromise, 7 days is non-inferior to 14. Pubmed: https://pubmed.ncbi.nlm.nih.gov/39565030/ Practice-Changing Takeaways Stable CAD + new anticoagulation? Stop aspirin if >6 months from PCI/CABG.Uncomplicated bacteremia? Seven days of antibiotics is sufficient in most cases (excluding Staph aureus and deep-seated infection).

    26 min

  3. FEB 12

    Episode 2: Phenobarbital for DTs, Conservative Dialysis for AKI, and Postop Transfusion Thresholds

    Send a text In Episode 2 of Inpatient Update, your host, Dr. Mason Turner, breaks down three studies that could change what you do on rounds tomorrow: Phenobarbital for alcohol withdrawal — fewer admissions and shorter ED stays during the IV lorazepam shortage natural experiment.Conservative dialysis in AKI requiring RRT (LIBERATE-D) — less routine dialysis, more kidney recovery?Postoperative transfusion thresholds in high–cardiac-risk patients (TOP Trial) — is 7 still enough?Articles & PubMed Links Fewer Admissions, Shorter Stays: Phenobarbital Use for Alcohol Withdrawal in the Emergency Department Academic Emergency Medicine (2025) PubMed: https://pubmed.ncbi.nlm.nih.gov/41147831/A Conservative Dialysis Strategy and Kidney Function Recovery in Dialysis-Requiring Acute Kidney Injury (LIBERATE-D Trial) JAMA ( 2026) PubMed: https://pubmed.ncbi.nlm.nih.gov/41201895/Liberal or Restrictive Postoperative Transfusion in Patients at High Cardiac Risk: The TOP Randomized Clinical Trial JAMA (2025) PubMed: https://pubmed.ncbi.nlm.nih.gov/41205227/REACH OUT: Have insight into inpatient medicine?  Article suggestion?  Interested in being a guest? Email or DM me.  Follow and subscribe wherever you listen so you never miss the next update.

    28 min

  4. FEB 3

    Episode 1: ERCP Antibiotics, Apixaban Dose in Cancer, and Early Beta-Blockers in Cirrhosis

    Send a text In this pilot episode of Inpatient Update, your host, Dr. Mason Turner, breaks down three clinically relevant studies that could change how you practice tomorrow on the wards: Pre-ERCP antibiotic prophylaxis — does it reduce post-procedure infections in biliary obstruction?Reduced-dose apixaban after 6 months in cancer-associated VTE — noninferior and potentially safer?Early initiation of beta-blockers in cirrhosis with uncomplicated ascites — early signals of benefit.Practical take-homes, clear links to evidence, and what to tell your team on rounds. Articles & PubMed Links Is Antibiotic Prophylaxis Warranted in All Patients With Biliary Obstruction Undergoing Endoscopic Retrograde Cholangiopancreatography?: A Systematic Review and Meta-Analysis PubMed: https://pubmed.ncbi.nlm.nih.gov/40961256/ Extended Reduced-Dose Apixaban for Cancer-Associated VTE (API-CAT) PubMed: https://pubmed.ncbi.nlm.nih.gov/40162636/ Efficacy and Safety of Carvedilol in Cirrhosis Patients With New-Onset Uncomplicated Ascites Without High-Risk Esophageal Varices (CARVE-AS Trial)  PubMed: https://pubmed.ncbi.nlm.nih.gov/40689908/

    18 min
  • 4 Episodes

About

Inpatient Update delivers short, practical reviews of new studies that matter to hospitalists—focused on what actually changes decisions on rounds tomorrow. Efficient, evidence-based, and built for the working clinician. 

Information

  • Creator
    Mason Turner, MD
  • Years Active
    2K
  • Episodes
    4
  • Rating
    Clean
  • Copyright
    © 2026 Inpatient Update
  • Show Website
    Inpatient Update